{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-293874","form_type":"8-K","ticker":"STTK","cik":"0001680367","company_name":"Shattuck Labs, Inc.","filed_at":"2023-12-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.043885+00:00","generated_at":"2026-06-07T13:31:36.377309+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Shattuck reports 79% ORR in frontline HR-MDS and 27% CR/CRi in TP53m AML from SL-172154 trial","bullets":["79% objective response rate (ORR) with 64% complete response (CR)/marrow CR in 14 evaluable frontline HR-MDS patients.","27% initial CR/CRi in 11 evaluable frontline TP53m AML patients; 5 achieved stable disease with decreasing blasts.","SL-172154 + azacitidine showed acceptable safety; no destructive anemia; most common TEAE was infusion-related reaction.","Cohorts expanding; Shattuck expects next data update by mid-2024.","Monotherapy response in R/R AML patient allowed stem cell transplant; patient remains disease-free."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-293874","json":"https://secwatch.observer/filing/0001193125-23-293874.json","markdown":"https://secwatch.observer/filing/0001193125-23-293874.md","text":"https://secwatch.observer/filing/0001193125-23-293874.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1680367/000119312523293874/0001193125-23-293874-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1680367/000119312523293874/d664766d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T13:31:36.377309+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}